Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Pacira BioSciences, Inc. reported the second quarter ended June 30, 2023 results: revenue Total revenues of $169.5 million, net income Net income of $25.8 million, EPS $0.56 per share (basic) and $0.51 per share (diluted). Guidance lowered.
- Period
- the second quarter ended June 30, 2023
- Revenue
- Total revenues of $169.5 million
- Net income
- Net income of $25.8 million
- EPS
- $0.56 per share (basic) and $0.51 per share (diluted)
- Guidance
- lowered
- Result
- reported results
Exact text from the filing
Total revenues of $169.5 million • Net product sales of $135.1 million for EXPAREL, $29.3 million for ZILRETTA, and $4.4 million for iovera° • Net income of $25.8 million, or $0.56 per share (basic) and $0.51 per share (diluted)
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Pacira BioSciences, Inc. updated its full year 2023 guidance (lowered).
- Period
- full year 2023
- Guidance
- lowered
- Result
- guidance update
Exact text from the filing
Pacira is revising the following full-year financial guidance: • EXPAREL net product sales of $550 million to $560 million versus the company’s previously guided range of $570 million to $580 million; • ZILRETTA net product sales of $110 million to $115 million versus the company’s previously guided range of $115 million to $125 million; • Non-GAAP gross margin of 73% to 74% versus the company’s previously guided range of 76% to 78%; and • Stock-based compensation of $46 million to $49 million versus the company’s previously guided range of $51 million to $54 million.
View on SEC.gov